Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 9
Submit an article Journal homepage
180
Views
44
CrossRef citations to date
0
Altmetric
Drug Evaluation

Atazanavir: a novel HIV-1 protease inhibitor

Peter J Piliero Associate Professor of Medicine, Albany Medical College, Division of Clinical Pharmacology, 47 New Scotland Avenue, MC 142, Albany, NY 12208, USA. [email protected]
Pages 1295-1301 | Published online: 24 Feb 2005

Bibliography

  • FISCHL MA, RICHMAN DD, GRIECO MH et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl. J. Med. (1987) 317:185–191.
  • HAMMER SM, KATZENSTEIN DA, HUGHES MD et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl. Med. (1996) 335:1081–1090.
  • KATZ RA, SHALKA AM: The retroviral enzymes. Ann. Rev Biochem. (1994) 63:133–173.
  • HAMMER SM, SQUIRES KE, HUGHES MD et al.:A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl. I Med. (1997) 337:725–733.
  • PALELLA FJ jR, DELANEY KM, MOORMAN AC et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl. J. Med. (1998) 338:853–860.
  • STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl. J. Med. (1999)15.341:1865–1873.
  • PATERSON DL, SWINDELLS S, MOHR J et al: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133:21–30.
  • ••This study set the benchmark for the rate ofadherence associated with the greatest likelihood of virological suppression. metabolic and morphologic abnormalities associated with human immunodeficiency virus. Gin. Infect. Dis. (2002) 34:248–259.
  • BARTLETT JA, DEMASI R, QUINN J, MOXHAM C, ROUSSEAU F: Overview of 17. the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS (2001) 15:1369–1377.
  • BARTLETT JA: Addressing the challenges of18.adherence. J. Acquit: Immune Defic. Synth: (2002) 29\(Suppl. 1):52–S10.
  • WANKE CA, FALUTZ JM, SHEVITZ A19.et al.: Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin. Infect. Dis. (2002) 34:248–259.
  • RICHMAN DD, BOZZETTE S, MORTON S et al.: The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA. December 16–19, 2002. Abstract LB–17.
  • BINI T, TESTA L, CHIESA E et al: Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. I Acquir. Immune Defic. Syndr. (2000) 24:115–122.
  • PILIERO PJ, CAHN P, PANTALEO Get al.: Atazanavir: A once-daily protease inhibitor with a superior lipid profile-results of clinical trials at week 48. 9th Conference on Retrovimses and Opportunistic Infections. Seattle, USA. February 23–28, 2002. Abstract 706–T.
  • •This abstract presents 48-week data of Phase II atazanavir studies in antiretroviral naive subjects.
  • HAAS DW, ZALA C, SCHRADER S, THIRY A, MCGOVERN R, SCHNITTMAN S: Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy. 9th Conference on Retro viruses and Opportunistic Infections. Seattle, USA. February 23–28, 2002. Abstract 42.
  • •This abstract presents 48-week data of Phase II atazanavir studies in antiretroviral experienced subjects.
  • BHIVA WRITING COMMITTEE: British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral agents. HIV Med. (2001) 2:276–313.
  • MANFREDI R, CHIODO F: Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. (2001) 42:181–188.
  • EISNER R: 'Hit later, hit hard' with AIDSdrugs: Federal government to announce new AIDS treatment policy. ABC News 31 January 2001.
  • RABASSEDA X, SILVESTRE J, CASTANER J: BMS-232632. Drugs of the Future (1999) 24:375–380.
  • ROBINSON BS, RICCARDI KA, GONG YI-FEI et al: BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other antiretroviral agents. Antimicrob. Agents Chemother. (2000) 44:2093–2099.
  • ••This paper reviews the in vitro and cellculture activity of atazanavir.
  • BILELLO JA, BILELLO PA, STELLRECHT K et al.: Human serum alpha 1 acid glycoprotein reduced uptake, intracellular concentration, and antiviral activity of A-80987, and inhibitor of the human immunodeficiency virus Type 1 protease. Antimicrob. Agents Chemother (1996) 40:1491–1497.
  • GONG Y-F, ROBINSON BS, ROSE RE et al. In vitro resistance profile of the Human Immunodeficiency Virus Type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother: (2000) 44:2319–2326.
  • ••This paper describes the selection and characterisation of atazanavir-resistant isolates in vitro.
  • COLONNO RJ, HERTOGS K, LIMOLI K, PARKIN N: BMS-232 sensitivity of a panel of HIV-1 clinical isolates resistant to one or more approved protease inhibitors Antimicrob. Agents Chemother. (2002). Submitted.
  • O'MARA E, SMITH J, OLSEN SJ, TANNER T, SCHUSTER AE, KAUL S: BMS-232632: Single-oral dose safety and pharmacokinetic study in healthy volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (1998) Abstract 1–242.
  • O'MARA E, SMITH J, OLSEN SJ, TANNER T, SCHUSTER AE, KAUL S: BMS-232632: Single and multiple oral dose safety and pharmacokinetic study in healthy volunteers. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (1999) Abstract 604.
  • DRUSANO GL, BILELLO JA, PRESTON SL: Hollow-fiber unit evaluation of a new human immunodeficiency virus Type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. I Infect. Dis. (2001) 183:1126–1129.
  • OMARA E, PILIERO P, DRUSANO G: BMS-232632: A preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor-naive HIV positive population. Abstract P9. 5th International Congress on Drug Therapy in HIV Infection. October 22–26, 2000. Glasgow, Scotland.
  • O'MARA E, RANDALL D, UDERMAN H et al.: Steady-state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada. September 17–20, 2000. Abstract 1646.
  • AGARWALA S, MUMMANENI V, RANDALL D, GERALDES M, STOLTZ R, O'MARA E: Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects. 9th Conference on Retrovimses and Opportunistic Infections. Seattle, USA. February 23–28, 2002. Abstract 445–W.
  • PRESTON S, PILIERO P, O'MARA E et al:Evaluation of the steady-state interaction between atazanavir and efavirenz. 9th Conference on Retrovimses and Opportunistic Infections. Seattle, USA. February 23–28, 2002. Abstract 443–W.
  • O'MARA E, MUMMANENI V, BIFANO M et al.: Pilot study of the interaction between BMS-232632 and ritonavir. 8th Conference on Retrovimses and Opportunistic Infections. Chicago, USA. February 4–8, 2002. Abstract 740.
  • O'MARA E, AGARWALA S, RANDALL D,GERALDES M, STOLTZ R, MUMMANENI V: Steady state pharmacolkinetic interaction study of atazanavir with efavirenz and ritonavir in healthy subjects. 9th Conference on Retrovimses and Opportunistic Infections. Seattle, USA. February 23–28, 2002. Abstract 444–W.
  • BOSMA P J., CHOWDHURY J. R., BAKKER C et al.: The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome. N Engl. J. Med. (1995) 333:1171–1175.
  • O'MARA E, MUMMANENI V, BURCHELL B et al.: Relationship between uridine diphosphate-glucuronosyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir (SQV). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada. September 17–20, 2000. Abstract 1645.
  • PILIERO PJ: Interaction Between Ritonavir and Statins [letter]. Am. J. Med. (2002) 112:510–511.

Websites

  • http://www.hivatis.org. PANEL ON CLINICAL PRACTICES FOR TREATMENT OF HIV INFECTION CONVENED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE HENRY J KAISER FAMILY FOUNDATION: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002.
  • ••Comprehensive evolving documentdiscussing critical aspects of antiretroviral therapy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.